Wednesday, 22 Jan 2020

PsA/SpA

Datesort ascending Type Title Save
28 Oct 2019 Social Metanalysis of 373 citations and 14 studies was unable to prove a protective X-ray benefit of TNF inhibitors in patients with axial spondyloarthritis. https://t.co/CSffpEEmHo
27 Oct 2019 Social Mediterranean diet study of 211 Psoriatic Arthritis patients. 27% had MetSyndr. Moderate adherence 66%. Disease activity (DAPSA, HAQ) was inversely correlated with diet adherence. The most active PsA had the lowest adherence https://t.co/2Yf22zEH2o
24 Oct 2019 Social Observational study of the meditteranean diet on 211 Psoriatic Arthritis patients. 27% had MetSyndr. Moderate adherence 66%. Disease activity (DAPSA, HAQ) was inversely correlated with diet adherence. The most active PsA had the lowest adherence https://t.co/2Yf22zEH2o
23 Oct 2019 Social Toronto longitudinal study of 1061 Psoriatic arthritis patients finds 343 had liver test abnormalities (prevalence 32%) w/ incidence rate of 39/1000 patient-years. Liver abnormalities were detected after a follow up duration of 8.3 ±7.8 years. https://t.co/FmAIJsPANu
23 Oct 2019 Social Matched cohort study of 3763 AS & 19,214 controls, shows that gout and AS can coexist - gout found in 1.94% of AS and 0.56% of controls (OR 3.53, P < 0.001). AS was independently associated with gout (OR 1.41, P = 0.037). https://t.co/y0bGpdOgoI
18 Oct 2019 Social RheumNow Podcast is up! The week in review - on statins, Comorbidities, ANA specificity, APL Ab effects, PsA surgery & more. Watch it here>> https://t.co/c0EPyvKNWD or listen to the podcast in your car (Android Auto, Apple Car play) or here>> https://t.co/xZWQTszGn9
16 Oct 2019 News Comorbidity Worsens Axial Spondyloarthritis
15 Oct 2019 News One-Third of Psoriatic Arthritis Patients Will Need Joint Surgery
15 Oct 2019 Social Followup of 783 tofacitinib‐treated psoriatic arthritis patients finds increases in LDL and HDL 9% to 14% after 3 and 6 months of therapy with a low risk of HTN or MACE events https://t.co/fh6UbmF3lr
08 Oct 2019 Social Note to Colleague: How can you possibly diagnose and treat ankylosing spondylitis in a patient with polyarthralgias, +B27 but nothing else (no enthesitis, Pso, IBD, Abnl Schobers and neg SI films)?? The diagnosis (poor sleep, tender points) was obvious. You know who you are
07 Oct 2019 News FUTURE 5 - Secukinumab and Less Radiographic Progression in Psoriatic Arthritis
04 Oct 2019 Social Claims study of RA, PsA, AS/SpA patients on TNF inhibitors shows a comparison of 31,527 MTX vs 34,651 TNFi initiators. MTX was D/C sooner in PsA & AS [aHR 1.10, 1.23) vs RA pts. Concomitant MTX reduced risk of TNFi D/C in all [aHR 0.85, 0.81, 0.79] https://t.co/0l2J2FDsUm
02 Oct 2019 News Ixekizumab vs. Adalimumab in Psoriatic Arthritis
30 Sep 2019 Social Tofacitinib therapy is being studied (not yet approved) in several dermatologic conditions - psoriasis, alopecia areata/universalis, vitiligo, atopic dermatitis and dermatomyositis. https://t.co/Ez3u95Eh7K
22 Sep 2019 Social Novartis announced 16 wk results from the PREVENT trial - secukinumab shown to have superior ASAS40 responses in active non-radiographic axial spondyloarthritis (nr-axSpA). They estimate there are 1.7 million with nr-axSpA in the EU and US. https://t.co/IamZNN7Itc
19 Sep 2019 News NSAID Use Linked With Hypertension in Ankylosing Spondylitis
19 Sep 2019 Social Prospective ankylosing spondylitis cohort - 628 without HTN F/U x12 mos; 200 Rx w/ NSAIDs; of these 129 developed incident HTN. NSAID use associated with incr risk of HTN (HR 1.12; CI, 1.04‐1.20), not effected by age, biologics, dz activity https://t.co/T6y5OcCgMM
18 Sep 2019 Social Novartis announced 16 wk results from the PREVENT trial - secukinumab shown to have superior ASAS40 responses in active non-radiographic axial spondyloarthritis (nr-axSpA). They estimate there are 1.7 million with nr-axSpA in the EU and US. https://t.co/IamZNN7Itc
17 Sep 2019 Social Review of 927 PSUMMIT PsA patients treated with Ustekinumab shows IL- 17A, IL- 17F & IL-23 correlated with baseline skin scores (r=0.26-0.62), but not joint or disease activity scores. No biomarker (IL- 17A/F, IL- 23, CRP) predicted ustekinumab responses https://t.co/JORFZj6QgJ
13 Sep 2019 Social TICOPA study was a T2T strategy trial in psoriatic arthritis to improve outcomes. 5 yr outcomes of 110 pts shows simlar low Dz activity in TC 69% vs SOC 76%. Biologic use was higher in TC ( 33%). Not much advantage to TC - just more biologics and less MTX https://t.co/3D890Z8bSS